Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at its genetic root, ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

Oral agent in second-line more than doubled median PFS in patients with ESR1 muta ...

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner's National Priority ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...

Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with ...

Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT ...

Discover 25 incredible facts about the human body that will blow your mind! From neurogenesis to daily height changes, ...

Between 280 and 200 million years ago, a group of animals evolved which would eventually give rise to mammals, including humans: the therapsids. They were first described more than 150 years ago, ...